Group 1 - The fifth meeting of the board of directors of Kew Flower Pharmaceutical Group Co., Ltd. was held on November 18, 2025, via telecommunication voting, with all nine directors participating [2][4]. - The board approved a proposal for product research and development, allocating up to 50 million yuan for projects including traditional Chinese medicine and generic drug development [3][5]. - The decision was made with unanimous support, receiving 9 votes in favor and no opposition or abstentions [4]. Group 2 - The meeting was convened by the chairwoman, Ms. Guan Yuxiu, and the notice and agenda were sent out on November 13, 2025 [2]. - The board's resolutions are valid and do not require submission to the shareholders' meeting for approval [5]. - The company ensures the accuracy and completeness of the information disclosed in the announcement [1].

Core Points - The company, Kew Flower Pharmaceutical Group Co., Ltd., announced a board resolution on November 18, 2025, to allocate up to 50 million yuan for product research and development, focusing on traditional Chinese medicine, generic drug consistency evaluation projects, and expanding indications for existing products [1][2] - The board meeting was conducted via telecommunication, with all 9 participating directors voting in favor of the proposal, indicating unanimous support for the R&D initiatives [1] - The R&D investment aims to optimize the product structure and enhance the company's core competitiveness, reinforcing its long-term development strategy in the pharmaceutical sector [2] Summary by Categories R&D Investment - The company plans to invest no more than 50 million yuan in R&D, targeting three main areas: traditional Chinese medicine, generic drug consistency evaluation, and expanding indications for existing products [1] - This investment is intended to enrich the product pipeline and strengthen the company's long-term growth potential [1][2] Board Meeting Details - The fifth board's thirteenth meeting was held on November 18, 2025, with all 9 directors participating and voting unanimously in favor of the R&D proposal [1] - The decision falls within the board's authority and does not require shareholder approval, allowing management to control the project’s progress [1] Strategic Focus - Kew Flower Pharmaceutical continues to focus on its core pharmaceutical business, with this R&D funding expected to enhance its position in the innovation of traditional Chinese medicine and the quality improvement of generic drugs [2]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Group 1 - The company, Kew Flower Pharmaceutical (002737.SZ), announced a plan to invest up to 50 million yuan for the development of traditional Chinese medicine with the same name and formula, generic drug projects aligned with consistency evaluation, and research to expand indications for existing products [1] - The management has been authorized to oversee the progress and specific matters related to the project development [1] - This initiative aims to enrich the product pipeline and strengthen the company's long-term development momentum [1]

Core Viewpoint - The company has approved a funding of up to 50 million yuan for various drug development projects, indicating a strategic focus on expanding its product offerings and enhancing its research capabilities [1] Group 1: Product Development Initiatives - The company will initiate research and development for traditional Chinese medicine with the same name and formula [1] - The company plans to develop generic drugs that are equivalent to the consistency evaluation projects [1] - There will be efforts to expand existing products by adding new indications [1] Group 2: Management and Oversight - The management team has been authorized to oversee the progress and specific matters related to the R&D projects [1] - The decision falls within the board's authority and does not require shareholder approval [1]